Chinese Journal of Pharmacovigilance ›› 2019, Vol. 16 ›› Issue (8): 504-505.
Previous Articles Next Articles
LI Jinwen, ZHANG Ping*, LIAO Yingxi, TIAN Jixin, WANG Xiaodan, LI Shan, YAN Haihong
Received:2019-09-09
Revised:2019-09-09
Online:2019-08-20
Published:2019-09-09
CLC Number:
LI Jinwen, ZHANG Ping, LIAO Yingxi, TIAN Jixin, WANG Xiaodan, LI Shan, YAN Haihong. One Case of Allergic Reaction and Paroxysmal Supraventricular Tachycardia Induced by Rituximab Injection[J]. Chinese Journal of Pharmacovigilance, 2019, 16(8): 504-505.
| [1] 段彦龙,金玲,杨菁,等.儿童伯基特白血病26例临床研究[J].首都医科大学学报,2016,37(2):141-147. [2] Teshima K, Ohyagi H, Kume M, et al.Refractory CD20-positive peripheral T-cell lymphoma showing loss of CD20 expression after rituximab therapy and gain of CD20 expression after administration of vorinostat and gemcitabine[J]. Rinsho Ketsueki, 2017, 58(11): 2227-2231. [3] Awasthi A, Rolland D C M, Ayello J, et al.A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment[J].Oncotarget, 2017, 8(69):113895-113909. [4] Singh V, Gupta D, Almasan A.Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immu-notherapy Response[J]. J Cancer Sci Ther, 2015, 7(11): 347-358. [5] Perry A M, Diebold J, Nathwani B N, et al.Non-Hodgkin lymphoma in the Far East: review of 730 cases from the international non-Hodgkin lymphoma classification project[J].Brit J Haematol, 2016, 172(5):716-723. [6] 刘卉,刘宇宏.CD20单核苷酸多态性对利妥昔单抗注射液治疗急性淋巴细胞白血病的影响[J].实用医学杂志,2018,34(16):2733-2736. [7] 张春涛. 不同剂量的利妥昔单抗注射液治疗视神经脊髓炎谱系疾病临床疗效观察[D].山西:山西医科大学, 2016. [8] 陈垚. 1例利妥昔单抗注射液注射液治疗弥漫大B细胞淋巴瘤并发喉头水肿患者的护理[J]. 中西医结合护理(中英文),2018,4(2):176-178. [9] 国家食品药品监督管理局药品安全监管司,国家药品不良反应中心.药品不良反应报告和监测工作手册[S]. 2005:46. |
| [1] | SUN Qiyue, ZHAO Ronghua, GUO Shanshan, BAO Lei, GENG Zihan, LI Shuran, XU Yingli, ZHANG Jingsheng, CUI Xiaolan, SUN Jing. Multiple pharmacological effects of Lingyang Ganmao Oral Liquid [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 127-131. |
| [2] | ZHAO Ronghua, SUN Jing, BAO Lei, GENG Zihan, TAO Xiali, ZHANG Jingsheng, PANG Bo, XU Yingli, CAO Shan, LI Shuran, GUO Shanshan, WANG Daohan, CUI Xiaolan. Mechanisms of Gegen Tang granules against viral pneumonia in mice based on immune regulation [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 132-136. |
| [3] | BAO Lei, GENG Zihan, LI Shuran, JI Zuen, ZHAO Ronghua, SUN Jing, GUO Shanshan, CUI Xiaolan. The critical role of TRP channels in the progression of viral pneumonia [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 137-140. |
| [4] | JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166. |
| [5] | LI Jiaxin, LIU Huimin, QIAN Wenxiu, MA Ning, SONG Lili, LI Yubo. Nephrotoxic effects and usage of traditional Chinese medicines based on the Traditional Chinese Medicine Systems Toxicology Database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 173-180. |
| [6] | FAN Kaikai, WANG Cong, LIU Hongfeng, WANG Xiyong. Effects of clinical pharmacist interventions on usage of alanyl-glutamine injections in a hospital [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 181-184. |
| [7] | ZHANG Jian, FANG Huihua. Applicability of evaluation standards for use of traditional Chinese medicine injections for promoting blood circulation and removing blood stasis [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 185-189. |
| [8] | WANG Shan, XIE Bo, LIU Huimin, LI Zhihao. Adverse event signals for celecoxib based on FAERS database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 190-194. |
| [9] | LI Yingfen, HAN Lei. Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198. |
| [10] | XU Weijia, PENG Qi, HUANG Haiyu, ZHANG Leijiao, XIAO Hua, WU Xue. 285 cases of adverse drug reaction related to new antineoplastic drugs [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 199-203. |
| [11] | GUO Qinghua, PENG Xiaoxiao, ZHU Ping, LIU Xilin, YANG Yinghua, CHEN Zhihai. One case of multiple organ dysfunction syndrome caused by amlodipine overdose [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 204-207. |
| [12] | FANG Meilin, ZHENG Huimin, WANG Cunze, WANG Ling, RUAN Junshan. One case of generalized myalgia caused by oxaliplatin [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 208-210. |
| [13] | LI Na, GUO Jun, GUO Wenjia, LYU Yinyin, LI Caihong, MU Xiangdong. One case of delayed skin allergic reaction caused by asthma treated with omalizumab injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 211-212. |
| [14] | CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili. One case of severe liver injury caused by Tianma Shouwu tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218. |
| [15] | ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie. Adverse reaction monitoring of toothpaste in China under the new regulatory system [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
